The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.

Nowrouzi-Sohrabi P, Rezaei S, Jalali M, Ashourpour M, Ahmadipour A, Keshavarz P, Akbari H

European journal of pharmacology19 Dec 2020Cited by 17 (Europe PMC)

PMID33352183DOI10.1016/j.ejphar.2020.173823PepBankPUB-33352183

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, pooled GLP-1 receptor agonists (mainly liraglutide and exenatide) reduced body mass index.
In plain wordsIn adults with type 2 diabetes and fatty liver disease, GLP-1 drugs as a group lowered body mass index compared with other therapies.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Comparator
Other therapies
Outcome group
Body weight · Metabolic and weight
Measurements
WMD
−1.57 kg/m2
BMI, GLP-1RAs pooled
Source sentences
Summary
GLP-1RAs intake significantly reduced body mass index (BMI) (WMD -1.57, 95%CI; -2.74, -0.39), waist-circumference (WC) (WMD -4.14, 95%CI; -7.09, -1.19), body weight (WMD -4.20, 95%CI; -8.15, -0.25) among the body mass indices.
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbA1c compared with other therapies in patients with T2DM and NAFLD.
Summary · context
This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM).
Summary · context
Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3335218301
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, pooled GLP-1 receptor agonists (mainly liraglutide and exenatide) reduced waist circumference.
In plain wordsIn adults with type 2 diabetes and fatty liver disease, GLP-1 drugs as a group reduced waist size compared with other therapies.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Other therapies
Outcome group
Body weight · Metabolic and weight
Measurements
WMD
−4.14 cm
waist circumference, GLP-1RAs pooled
Source sentences
Summary
GLP-1RAs intake significantly reduced body mass index (BMI) (WMD -1.57, 95%CI; -2.74, -0.39), waist-circumference (WC) (WMD -4.14, 95%CI; -7.09, -1.19), body weight (WMD -4.20, 95%CI; -8.15, -0.25) among the body mass indices.
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbA1c compared with other therapies in patients with T2DM and NAFLD.
Summary · context
This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM).
Summary · context
Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3335218302
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, pooled GLP-1 receptor agonists (mainly liraglutide and exenatide) reduced body weight.
In plain wordsIn adults with type 2 diabetes and fatty liver disease, GLP-1 drugs as a group lowered body weight compared with other therapies.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Other therapies
Outcome group
Body weight · Metabolic and weight
Measurements
WMD
−4.2 kg
body weight, GLP-1RAs pooled
Source sentences
Summary
GLP-1RAs intake significantly reduced body mass index (BMI) (WMD -1.57, 95%CI; -2.74, -0.39), waist-circumference (WC) (WMD -4.14, 95%CI; -7.09, -1.19), body weight (WMD -4.20, 95%CI; -8.15, -0.25) among the body mass indices.
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbA1c compared with other therapies in patients with T2DM and NAFLD.
Summary · context
This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM).
Summary · context
Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3335218303
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, pooled GLP-1 receptor agonists (mainly liraglutide and exenatide) lowered postprandial plasma glucose.
In plain wordsIn adults with type 2 diabetes and fatty liver disease, GLP-1 drugs as a group lowered blood sugar after meals compared with other therapies.
Peptide
Liraglutide
Outcome
DecreasePostprandial plasma glucose
Study
n: not reported in source
Comparator
Other therapies
Outcome group
Glycemic control · Metabolic and weight
Measurements
WMD
−25.73 mg/dl
PPG, GLP-1RAs pooled
Source sentences
Summary
Additionally, GLP-1RAs leads to lower postprandial plasma glucose (PPG) levels (WMD -25.73 mg/dl, 95%CI; -32.71, -18.75).
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbA1c compared with other therapies in patients with T2DM and NAFLD.
Summary · context
This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM).
Summary · context
Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3335218304
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, pooled GLP-1 receptor agonists (mainly liraglutide and exenatide) had no significant effect on waist-hip ratio.
In plain wordsIn adults with type 2 diabetes and fatty liver disease, GLP-1 drugs as a group did not clearly change waist-hip ratio compared with other therapies.
Peptide
Liraglutide
Outcome
No significant changeWaist-hip ratio
Study
n: not reported in source
Comparator
Other therapies
Outcome group
Body weight · Metabolic and weight
Measurements
WMD
−0.01 ratio
WHR, GLP-1RAs pooled
Source sentences
Summary
We also found that GLP-1RAs intake has no significant effect on the waist-hip ratio (WHR) (WMD -0.01, 95%CI; -0.03, 0.02), fasting blood glucose (FBG) (WMD -2.12 mg/dl, 95%CI; -6.23, 1.96), hemoglobin A1c (HbA1c) (WMD -0.08%, 95%CI; -0.21, 0.04), and homeostatic model assessment for insulin resistan…
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbA1c compared with other therapies in patients with T2DM and NAFLD.
Summary · context
This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM).
Summary · context
Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3335218305
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, pooled GLP-1 receptor agonists (mainly liraglutide and exenatide) had no significant effect on fasting blood glucose.
In plain wordsIn adults with type 2 diabetes and fatty liver disease, GLP-1 drugs as a group did not clearly change fasting blood sugar versus other therapies.
Peptide
Liraglutide
Outcome
No significant changeFasting blood glucose
Study
n: not reported in source
Comparator
Other therapies
Outcome group
Glycemic control · Metabolic and weight
Measurements
WMD
−2.12 mg/dl
FBG, GLP-1RAs pooled
Source sentences
Summary
We also found that GLP-1RAs intake has no significant effect on the waist-hip ratio (WHR) (WMD -0.01, 95%CI; -0.03, 0.02), fasting blood glucose (FBG) (WMD -2.12 mg/dl, 95%CI; -6.23, 1.96), hemoglobin A1c (HbA1c) (WMD -0.08%, 95%CI; -0.21, 0.04), and homeostatic model assessment for insulin resistan…
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbA1c compared with other therapies in patients with T2DM and NAFLD.
Summary · context
This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM).
Summary · context
Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3335218306
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, pooled GLP-1 receptor agonists (mainly liraglutide and exenatide) had no significant effect on HbA1c.
In plain wordsIn adults with type 2 diabetes and fatty liver disease, GLP-1 drugs as a group did not clearly change HbA1c versus other therapies.
Peptide
Liraglutide
Outcome
No significant changeHemoglobin A1c
Study
n: not reported in source
Comparator
Other therapies
Outcome group
Glycemic control · Metabolic and weight
Measurements
WMD
−0.08%
HbA1c, GLP-1RAs pooled
Source sentences
Summary
We also found that GLP-1RAs intake has no significant effect on the waist-hip ratio (WHR) (WMD -0.01, 95%CI; -0.03, 0.02), fasting blood glucose (FBG) (WMD -2.12 mg/dl, 95%CI; -6.23, 1.96), hemoglobin A1c (HbA1c) (WMD -0.08%, 95%CI; -0.21, 0.04), and homeostatic model assessment for insulin resistan…
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbA1c compared with other therapies in patients with T2DM and NAFLD.
Summary · context
This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM).
Summary · context
Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3335218307
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, pooled GLP-1 receptor agonists (mainly liraglutide and exenatide) had no significant effect on HOMA-IR.
In plain wordsIn adults with type 2 diabetes and fatty liver disease, GLP-1 drugs as a group did not clearly change insulin resistance compared with other therapies.
Peptide
Liraglutide
Outcome
No significant changeHOMA-IR
Study
n: not reported in source
Comparator
Other therapies
Outcome group
Glycemic control · Metabolic and weight
Measurements
WMD
−0.31 unitless
HOMA-IR, GLP-1RAs pooled
Source sentences
Summary
We also found that GLP-1RAs intake has no significant effect on the waist-hip ratio (WHR) (WMD -0.01, 95%CI; -0.03, 0.02), fasting blood glucose (FBG) (WMD -2.12 mg/dl, 95%CI; -6.23, 1.96), hemoglobin A1c (HbA1c) (WMD -0.08%, 95%CI; -0.21, 0.04), and homeostatic model assessment for insulin resistan…
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbA1c compared with other therapies in patients with T2DM and NAFLD.
Summary · context
This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM).
Summary · context
Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3335218308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.

Summary

Results from this study8

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms

Keywords